Pneumocystis Pneumonia in Patients with Rheumatic Diseases Receiving Prolonged, Non-high-dose Steroids-clinical Implication of Primary Prophylaxis Using Trimethoprim-sulfamethoxazole

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2019 Sep 16

PMID 31521185

Citations 32

Authors

Jun Won Park

Jeffrey R Curtis

Min Jung Kim

Hajeong Lee

Yeong Wook Song

Eun Bong Lee

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the incidence of pneumocystis pneumonia (PCP) and its risk factors in patients with rheumatic disease receiving non-high-dose steroid treatment, along with the risks and benefits of PCP prophylaxis.

Methods: This study included 28,292 treatment episodes with prolonged (≥ 4 weeks), non-high-dose steroids (low dose [< 15 mg/day, n = 27,227] and medium dose [≥ 15 to < 30 mg/day, n = 1065], based on prednisone) over a 14-year period. Risk factors for PCP and prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) were investigated if the 1-year incidence rate (IR) of PCP in each dose group was > 0.1/100 person-years. Cox regression with LASSO was used for analysis.

Results: One-year PCP IR in the low-dose group was 0.01 (95% CI 0.001-0.03)/100 person-years, and only the medium-dose group showed eligible PCP IR for further analysis. In the medium-dose group, prophylactic TMP-SMX was administered in 45 treatment episodes while other episodes involved no prophylaxis (prophylaxis group vs. control group). In 1018.0 person-years, 5 PCP cases occurred exclusively in the control group, yielding an IR of 0.5 (0.2-1.2)/100 person-years. Concomitant steroid-pulse treatment and baseline lymphopenia were the most significant risk factors for PCP. Treatment episodes with at least one of these factors (n = 173, high-risk subgroup) showed higher 1-year PCP IR (3.4 (1.1-8.0)/100 person-years), while no PCP occurred in other treatment episodes. TMP-SMX numerically reduced the risk (adjusted HR = 0.2 (0.001-2.3)) in the high-risk subgroup. The IR of adverse drug reactions (ADRs) related to TMP-SMX was 41.5 (22.3-71.6)/100 person-years, including one serious ADR. The number needed to treat with TMP-SMX to prevent one PCP in the high-risk subgroup (31 (17-226)) was lower than the number needed to harm by serious ADR (45 (15-∞)).

Conclusion: Incidence of PCP in patients with rheumatic diseases receiving prolonged, medium-dose steroids depends on the presence of risk factors. Prophylactic TMP-SMX may have greater benefit than potential risk in the high-risk subgroup.

Citing Articles

The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia.

Price C, Wood J, Ismail I, Smith S, Hanson J Pathogens. 2024; 13(11).

PMID: 39599496 PMC: 11597851. DOI: 10.3390/pathogens13110943.

The characteristics and clinical course of patients with melioidosis and cancer.

Shukla T, Smith S, Johnstone K, Donald P, Hanson J PLoS Negl Trop Dis. 2024; 18(10):e0012631.

PMID: 39453944 PMC: 11540213. DOI: 10.1371/journal.pntd.0012631.

Clinical characteristics and prognosis of interstitial lung disease in systemic juvenile idiopathic arthritis: a two-center retrospective observational cohort study.

Zhan W, Yang J, Qiu L, Yang K, Ye X, Shangguan Y Pediatr Rheumatol Online J. 2024; 22(1):96.

PMID: 39449050 PMC: 11515563. DOI: 10.1186/s12969-024-01028-5.

The role of trimethoprim/sulfamethoxazole in preventing opportunistic infections in systemic lupus erythematosus patients receiving low-level immunosuppressive treatment: an open-label, randomized, controlled trial.

Munthananuchat P, Ngamjanyaporn P, Pisitkun P, Rotjanapan P Clin Exp Med. 2024; 24(1):241.

PMID: 39425800 PMC: 11490444. DOI: 10.1007/s10238-024-01503-z.

Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study.

Miyake K, Senoo S, Shiiba R, Itano J, Kimura G, Kawahara T PLoS One. 2024; 19(2):e0292507.

PMID: 38330061 PMC: 10852346. DOI: 10.1371/journal.pone.0292507.

References

Chen M, Tian X, Qin F, Zhou J, Liu J, Wang M . Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death. PLoS One. 2015; 10(9):e0139144. PMC: 4589243. DOI: 10.1371/journal.pone.0139144. View

Cereser L, Dallorto A, Candoni A, Volpetti S, Righi E, Zuiani C . Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT) in non-HIV immunocompromised patients: Spectrum of findings and mimickers. Eur J Radiol. 2019; 116:116-127. DOI: 10.1016/j.ejrad.2019.04.025. View

Heinze G, Schemper M . A solution to the problem of separation in logistic regression. Stat Med. 2002; 21(16):2409-19. DOI: 10.1002/sim.1047. View

Teichtahl A, Morrisroe K, Ciciriello S, Jennens I, Tadros S, Wicks I . Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patients. Semin Arthritis Rheum. 2015; 45(1):86-90. DOI: 10.1016/j.semarthrit.2015.01.007. View

Morris A, Lundgren J, Masur H, Walzer P, Hanson D, Frederick T . Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004; 10(10):1713-20. PMC: 3323247. DOI: 10.3201/eid1010.030985. View

Buttgereit F, Straub R, Wehling M, Burmester G . Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004; 50(11):3408-17. DOI: 10.1002/art.20583. View

Suyama Y, Okada M, Rokutanda R, Min C, Sasse B, Kobayashi D . Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study. Mod Rheumatol. 2015; 26(4):557-61. DOI: 10.3109/14397595.2015.1112467. View

Mansharamani N, Garland R, Delaney D, Koziel H . Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000; 118(3):704-11. DOI: 10.1378/chest.118.3.704. View

Wu A, Cheng V, Tang B, Hung I, Lee R, Hui D . The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect Dis. 2004; 4(1):57. PMC: 539247. DOI: 10.1186/1471-2334-4-57. View

10.

Jeffries M, Bruner G, Glenn S, Sadanandan P, Carson C, Harley J . Sulpha allergy in lupus patients: a clinical perspective. Lupus. 2008; 17(3):202-5. DOI: 10.1177/0961203307086640. View

11.

Yale S, Limper A . Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71(1):5-13. DOI: 10.4065/71.1.5. View

12.

Sepkowitz K, Brown A, Telzak E, Gottlieb S, Armstrong D . Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992; 267(6):832-7. View

13.

Park J, Curtis J, Moon J, Song Y, Kim S, Lee E . Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2017; 77(5):644-649. PMC: 5909751. DOI: 10.1136/annrheumdis-2017-211796. View

14.

Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M . The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev. 2011; 10(6):305-10. DOI: 10.1016/j.autrev.2010.11.009. View

15.

Sepkowitz K . Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002; 34(8):1098-107. DOI: 10.1086/339548. View

16.

Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M . Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology. 2009; 15(1):126-31. DOI: 10.1111/j.1440-1843.2009.01660.x. View

17.

Sowden E, Carmichael A . Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004; 4:42. PMC: 526257. DOI: 10.1186/1471-2334-4-42. View

18.

Suryaprasad A, Stone J . When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum. 2008; 59(7):1034-9. DOI: 10.1002/art.23822. View

19.

Mecoli C, Saylor D, Gelber A, Christopher-Stine L . Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol. 2017; 35(4):671-673. View

20.

Thomas Jr C, Limper A . Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007; 5(4):298-308. DOI: 10.1038/nrmicro1621. View